HDAC11 and hepatocellular carcinoma: For example, the highly selective HDAC11 inhibitor B6 has demonstrated favorable pharmacokinetics in the treatment of metabolic dysfunction-associated fatty liver disease [60], and selective inhibition of HDAC6 by N-acylhydrazone can suppress hepatocellular carcinoma progression [61].